ClinicalTrials.gg
Active, not recruitingNCT01639690Updated Apr 24, 2026

ß-Thalassemia Major With Autologous CD34+ Hematopoietic Progenitor Cells Transduced With TNS9.3.55 a Lentiviral Vector Encoding the Normal Human ß-Globin Gene

A Phase 1 interventional study of Autologous CD34+ cells transduced with TNS9.3.55 in Confirmed Diagnosis of ß-thalassemia Major, sponsored by San Rocco Therapeutics. Active, not recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-24.

Sponsored by San Rocco Therapeutics · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 49 studies in beta-Thalassemia with a site in Italy — 8 open to participants now, 17 under way, 6 of them phase 3. beta-Thalassemia · Italy.

Planned enrollment
36th of 39
10 · median 55
Started
2012
with 4 others
Phase 1
Only one
of the 49
Primary completion
2027-07
later than 9 of 16 live
Registered
11th of 49
by date

Among the 49 studies in beta-Thalassemia with a site in Italy, this one is the 36th largest by planned enrollment of the 39 interventional ones that give a count, is one of 5 that started in 2012, is the only one in phase 1, reaches primary completion later than 9 of the 16 other live ones, and was the 11th registered.

beta-Thalassemia

295 studies on the registry are indexed under beta-Thalassemia; 70 are open to participants now.

Browse beta-Thalassemia studies →

Open to participants now

8 of the 49 studies in beta-Thalassemia with a site in Italy are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 43 beta-Thalassemia studies recruiting now, 10 (23%) set no upper age limit and 31 (72%) stop at 75 or younger; 34 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in beta-Thalassemia with a site in Italy, or all of them as a file.
02

Study summary

The patient has inherited ß-thalassemia major through the genes. These genes have mistakes in them, so the body cannot make normal red blood cells. Stem cells are made in the bone marrow. They are the earliest form of blood cells.

This study is being done to see if the investigators can make the stem cells produce normal red blood cells and hemoglobin. The investigators do this by collecting the stem cells. The genes with mistakes are removed from the cells. These cells are then treated so they have the corrected gene for making normal hemoglobin. These treated cells are given back to the patient through an injection (shot) in the vein. This is also known as gene transfer. In order for the body to accept these cells, the patient will need to receive a low dose of a drug called busulfan. It is a drug that will prepare the body to receive the new stem cells.

This study will let the investigators know:

  • If it is safe to give the patient the treated stem cells
  • If the treated stem cells will go into the bone marrow without causing side effects.

Gene transfer has been used for the past five years. It has been successful in treating many blood disorders. At least 20 patients have received the type of treatment that the patient will get on this study. This treatment for B-thalassemia major was developed at Memorial Sloan Kettering (MSK). It was studied for a long time in the lab before being given to patients.

03

Conditions studied

  • Confirmed Diagnosis of ß-thalassemia Major

Browse trials for

Keywords

  • BUSULFAN
  • G-CSF
  • CliniMACS-CD34 Reagent System
  • Blood transfusion
  • 10-164
  • Autologous CD34+ cells transduced with TNS9.3.55, a lentiviral vector encoding the human β-globin gene
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must be 18 years or older
  • Subjects may be of either gender or of any ethnic background
  • Subjects must have a confirmed diagnosis of ß-thalassemia major and have been enrolled in a hypertransfusion program with a confirmed annual transfusion of ≥100 mL/kg/yr but \< 200 mL/kg/yr, AND ≥ 8 transfusions of blood per year over a minimum of two years.
  • Patients must NOT have an HLA-matched sibling
  • Patients must be off hydroxyurea (HU) or erythropoietin (EPO) treatment for at least three months prior to entry onto the study
  • Subjects must have a performance score of ≥70% at the time of entry into the study.
  • Subjects must have liver iron value of \< 15 mg/g/dry weight Iron quantitation may be performed by imaging such as T2*MRI or by
  • Subjects must have no evidence of cirrhosis** of the liver. Fibrosis of the liver can be tested by Fibroscan (47, 48, 49), or by liver biopsy. These should be performed within approximately a one year period prior to entry onto the study.
  • Subjects with an evaluation of cardiac function indicating:
  • normal function on (Multiple Gated Acquisition scan) or other methodology.

And

  • Patients must have a left ventricular ejection fraction (LVEF) of ≥ 60% and/or T2*MRI cardiac evaluation with T2* ≥20 milliseconds
  • Subjects with asymptomatic pulmonary function based on Lung Diffusion Testing DLCO Test DLCO ≥ 50% of predicted (corrected for )
  • Subjects with a determination of renal function based on: serum creatinine \< than or = to 1.5 mg/dL or if serum creatinine is outside the normal range, then > 60-ml/min/1.73 m2
  • Subjects must have adequate hepatic function based on:
  • \< 3 x and
  • \< 2.0 total serum (unless secondary to hemolysis)
  • Patients must be available for follow-up evaluations at 30, 60, 180 days post BMT and yearly thereafter indefinitely.

    • The possibility of unrelated donor stem cell transplantation will be discussed with patients, and a "preliminary" search for an unrelated donor may be done at the request of the patient. However, the finding of a potential HLA-matched unrelated donor will not exclude the patient from participating into this trial).

      • As the inclusion criteria are more specific than the Lucarelli/Pesaro thalassemia pre-transplant classification (Class 1,2 or 3 according to presence or absence of fibrosis, adequate chelation and/or hepatomegaly), the criteria stated above will be used in lieu of the Lucarelli/Pesaro classification.

Exclusion criteria

Exclusion Criteria:

  • Active infections including and ***,
  • Active infections including HTLV 1 and 2, and 1 and 2
  • Patients with treated HLTV or HIV
  • Diabetes Mellitus
  • Bone Marrow myelodysplasia and/or chromosomal abnormalities
  • Female patient pregnant or breast feeding
  • Patients with uncontrolled seizure disorders
  • Patients with severe pulmonary hypertension Tricuspid Jet velocity > 2.5 m/sec
  • Family history of familial cancer syndromes (leukemia, breast, ovarian, colorectal, etc.)

    *** Definition of active Hepatitis C include:

  • Positive HCV RNA Viral load by quantitative PCR testing Or if Negative HCV RNA viral load BUT on antiviral treatment
  • Liver with pathologic evidence of
  • Necrosis and inflammation around the portal areas - piecemeal necrosis or interface hepatitis or necrosis of hepatocytes and focal inflammation in the liver parenchyma.
  • Inflammatory cells in the portal areas ("portal inflammation").
  • Fibrosis, with early stages being confined to the portal tracts, intermediate stages being expansion of the portal tracts and bridging between portal areas or to the central area, and late stages being frank cirrhosis characterized by architectural disruption of the liver with fibrosis and regeneration.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Autologous CD34+ cells transduced with TNS9.3.55

    An open label study using a non-myeloablative conditioning regimen of busulfan and 1 or several infusions of autologous hematopoietic stem cells transduced with a lentiviral vector encoding the human ß-globin gene.

    Genetic: Autologous CD34+ cells transduced with TNS9.3.55

Interventions

  • GeneticAutologous CD34+ cells transduced with TNS9.3.55

    Patients will receive Filgrastim followed by apheresis of peripheral blood stem cells. CD34+ cells will be purified and transduced ex vivo. Transduced cells will be frozen in several aliquots whenever possible while vector copy number determination and biosafety testing are performed. Patients will be treated in the outpatient and/or inpatient units, and receive intravenous busulfan (8mg/kg) as non-myeloablative conditioning. Patients will be administered 2-12 x 10\^6 transduced CD34+ cells per kg in 1 or several infusions. A back-up of 2 x 10\^6 untransduced CD34+ cells per kg will be preserved for every patient.

    Also known as: Patient treatment with Filgrastim will last for up to 6 days with apheresis, collection on days 4 and 5 or days 5 or 6 if required. Reduced Intensity Conditioning will, consist of two days of busulfan treatment with an interval of two days prior to transplantation., Intravenous infusion of autologous CD34+ cells transduced with TNS9.3.55 will, be administered over 15-30 minutes in a volume of approximately 50 to 250 mL, on day 0. Subsequent infusions of autologous CD34+ cells transduced with TNS9.3.55, may be administered on day +1 or thereafter.

06

What researchers measure

Primary outcomes

  1. safety

    of transplanted autologous CD34+ hematopoietic cells that are transduced ex vivo with TNS9.3.55 and transplanted in subjects with ß-thalassemia major conditioned with a reduced-intensity non-myeloablative preparative regimen. 1. The occurrence of insertional oncogenesis, which will be investigated by monitoring peripheral blood cell counts and leukocyte clonality using FACS analysis, qPCR for vector. copy number, LAM-PCR and/or 454 sequencing; 2. The generation of a replication-competent lentivirus (RCL). 3. The safety of a low dose non-myeloablative conditioning regimen

    Time frame: 2 years

  2. tolerability

    of transplanted autologous CD34+ hematopoietic cells that are transduced ex vivo with TNS9.3.55 \& transplanted in subjects with ß-thalassemia major conditioned with a reduced-intensity non-myeloablative preparative regimen. monitoring the following: 1. The occurrence of insertional oncogenesis, which will be investigated by monitoring peripheral blood cell counts \& leukocyte clonality using FACS analysis, qPCR for vector. copy number, LAM-PCR and/or 454 sequencing; 2.The generation of a replication-competent lentivirus (RCL). 3.The safety of a low dose non-myeloablative conditioning regimen

    Time frame: 2 years

Secondary outcomes

  1. the level of engraftment

    of the genetically modified autologous CD34+ cells and expression of the transduced ß-globin gene as measured by: Blood for measurement of vector copy number and transgene expression in blood cells at months 1, 2 and 3. \- Bone Marrow Samples for evaluation of CFU, BFU-E gene+ colonies and Q-PCR will be tested at month 1.

    Time frame: 2 years

  2. The frequency of post transplant palliative transfusions

    The number of red blood cell transfusions after engraftment will be quantitatively evaluated for efficacy purposes.

    Time frame: 2 years

07

Study locations

1 site
  • Hospital "V.Cervello" Uoc Ematologiaii E Malattie Rare
    Palermo, 90146, Italy
08

References and documents

Publications

  • Boulad F, Maggio A, Wang X, Moi P, Acuto S, Kogel F, Takpradit C, Prockop S, Mansilla-Soto J, Cabriolu A, Odak A, Qu J, Thummar K, Du F, Shen L, Raso S, Barone R, Di Maggio R, Pitrolo L, Giambona A, Mingoia M, Everett JK, Hokama P, Roche AM, Cantu VA, Adhikari H, Reddy S, Bouhassira E, Mohandas N, Bushman FD, Riviere I, Sadelain M. Lentiviral globin gene therapy with reduced-intensity conditioning in adults with beta-thalassemia: a phase 1 trial. Nat Med. 2022 Jan;28(1):63-70. doi: 10.1038/s41591-021-01554-9. Epub 2022 Jan 3. PubMed 34980909 ↗
  • Boulad F, Wang X, Qu J, Taylor C, Ferro L, Karponi G, Bartido S, Giardina P, Heller G, Prockop SE, Maggio A, Sadelain M, Riviere I. Safe mobilization of CD34+ cells in adults with beta-thalassemia and validation of effective globin gene transfer for clinical investigation. Blood. 2014 Mar 6;123(10):1483-6. doi: 10.1182/blood-2013-06-507178. Epub 2014 Jan 15. PubMed 24429337 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2012, a primary completion of Jul 2027 and a completion of Jul 2027. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2012
First posted
Jul 13, 2012
Start
Jul 2012
Primary completionEst.
Jul 2027
CompletionEst.
Jul 2027
Last update
Apr 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01639690
Lead sponsor
San Rocco Therapeutics
Responsible party
Sponsor
First posted
Jul 13, 2012
Start date
Jul 2012
Primary completion
Jul 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Apr 24, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion